Published in final edited form as:

Psychiatr Clin North Am. 2010 March ; 33(1): 159–180. doi:10.1016/j.psc.2009.12.004.

Molecular Genetics of Attention Deficit Hyperactivity Disorder

Stephen V. Faraone, Ph.D.¹ and Eric Mick, Sc.D.²

¹ Departments of Psychiatry and Neuroscience & Physiology, SUNY Upstate Medical University

² Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School

Summary

Although twin studies demonstrate that ADHD is a highly heritable condition, molecular genetic studies suggest that the genetic architecture of ADHD is complex. The handful of genome-wide linkage and association scans that have been conducted thus far show divergent findings and are, therefore, not conclusive. Similarly, many of the candidate genes reviewed here (i.e. *DBH*, *MAOA*, *SLC6A2*, *TPH-2*, *SLC6A4*, *CHRNA4*, *GRIN2A*) are theoretically compelling from neurobiological systems perspective but available data are sparse and inconsistent. However, candidate gene studies of ADHD have produced substantial evidence implicating several genes in the etiology of the disorder, with meta-analyses supportive of a role of the genes coding for *DRD4*, *DRD5*, *SLC6A3*, *SNAP-25*, and *HTR1B* in the etiology of ADHD.

Introduction

Attention deficit/hyperactivity disorder (ADHD) is among the most common childhood onset psychiatric disorders. The world-wide prevalence of ADHD in children is eight to twelve percent [1] and the prevalence of ADHD in adults in the United States was estimated to be four percent in the National Comorbidity Survey [2]. Early studies found the risk of ADHD among parents of children with ADHD to be increased by between two and eight-fold with similarly elevated risk among the siblings of ADHD subjects (for a review of this literature see [3]). Faraone et al [4] extended these findings to families ascertained via adult probands meeting criteria for either full DSM-IV ADHD or late-onset ADHD.

However, adoption and twin studies are necessary to disentangle genetic from environmental sources of transmission observed in family studies. Three studies found that biological relatives of ADHD [5] or hyperactive children [6,7] were more likely to have hyperactivity than adoptive relatives. A more direct method of examining the heritability of ADHD is to study twins: the extent to which monozygotic twins are more concordant for ADHD than dizygotic twins can be used to compute the degree to which variability in ADHD in the population can be accounted for by genes (i.e., heritability). Faraone et al [8] reviewed 20 twin studies from the United States, Australia, Scandinavia and the European Union and reported a mean heritability estimate of 76%, showing that ADHD is among the most heritable of psychiatric disorders.

Genetic Linkage Studies

In an attempt to find regions of chromosomes which might harbor genes for ADHD, three groups have conducted genome-wide linkage scans. This approach examines many DNA

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

markers across the genome to determine if any chromosomal regions are shared more often than expected among ADHD family members. A study of 126 American affected sib-pairs found three regions showing some evidence of linkage (LOD scores >1.5): 5p12, 10q26, 12q23, and 16p13 [9]. An expanded sample of 203 families found stronger evidence for the 16p13 region, previously implicated in autism, with a maximum LOD score of 4 [10]. A study of 164 Dutch affected sib-pairs also identified a peak previously noted in autism, at 15q15, with a peak LOD score of 3.5 [11]. Two other peaks, at 7p13 and 9q33, yielded LOD scores of 3.0 and 2.1, respectively. A genome-wide scan of families from a genetically-isolated community in Columbia implicated 8q12, 11q23, 4q13, 17p11, 12q23, and 8p23 [12]. Pooled analyses of [10,11] suggest that the genetic background in the differing populations is quite distinct and that the lack of consistent findings is a reflection of this between-population heterogeneity [13] but did identify an area of linkage in these pooled analyses (5p13) that may reflect a common risk locus. A study of 155 sib-pairs from Germany reported a maximum LOD score of 2.59 for chromosome 5p at 17cM. They also reported nominal evidence for linkage to chromosomes 6q, 7p, 9q, 11q, 12q and 17p, which had also been identified in previous scans [14].

Although there is some overlap in nominally significant linkage peaks, there is no evidence for the replication of a genome-wide significant finding using strict criteria [15]. To determine if there were any common linkage signals among these studies, Zhou et al. [16] conducted a Genome Scan Meta Analysis of these data. They reported genome-wide significant linkage ($P_{SR}=0.00034$, $P_{OR}=0.04$) for a region on chromosome 16 between 64Mb and 83Mb. Although this finding is intriguing and worthy of follow-up, the lack of significant findings for other loci suggests that many genes of moderately large effect are unlikely to exist and that the method of association will be more fruitful in the search for ADHD susceptibility genes.

Genetic Association Studies

In contrast to the scarcity of linkage studies, many candidate gene association studies have been conducted. Several meta-analyses suggest strong association with ADHD and the *dopamine D4 receptor* gene (*DRD4*, 48-bp VNTR; [17,18]), the *dopamine D5 receptor* gene (*DRD5*, 148-bp microsatellite marker; [17,19]), the *dopamine beta-hydroxylase* gene (*DBH*, 5' taq1 A allele; [8]), the *synaptosomal-associated protein 25* gene (*SNAP-25*, T1065G single-nucleotide polymorphism (SNP), [8]), the *serotonin transporter* gene (*SLC6A4*, 44-bp insertion/deletion in the promoter region (5-HTTLPR); [8]) and the *serotonin 1B receptor* gene (*HTR1B*, *G861C* SNP; [8]). Meta-analysis has also suggested a weak association with ADHD and the *dopamine transporter* gene (*SLC6A3*, 480-bp VNTR in the 3' untranslated region (UTR); [17,20,21]), but no association with the *catechol-O-methyltransferase* gene (*COMT*, Val108Met polymorphism, [22]).

A major advance in the molecular genetics of ADHD was the publication of the International Multisite ADHD Gene (IMAGE) project in which 51 genes were analyzed for association with ADHD. Families were recruited via an ADHD combined-type child proband (N=674) who had at least one full sibling (n=808) and one biological parent (N=1227 parents) available for study. A high density SNP map was constructed for genes involved in the regulation of neurotransmitter pathways implicated in ADHD (dopamine, norepinephrine, and serotonin) based on tagging SNPs and SNPs within known functional regions. This study is the most in-depth genetic association study performed in the largest set of ADHD patients to date and found evidence of association with ADHD and 18 genes.

Taken together this literature strongly suggests a contribution of genetic factors in the etiology of ADHD. In this review, we provide an update on the progress of molecular genetic studies published since the completion of these meta-analyses. Results from the IMAGE project will be discussed separately for each gene.

Association Studies of Catecholaminergic Genes

The Dopamine D4 receptor (DRD4)

Both noradrenaline and dopamine are potent agonists of *DRD4* [23], and the D4 receptor is prevalent in frontal-subcortical networks implicated in the pathophysiology of ADHD by neuroimaging and neuropsychological studies [24]. Researchers have predominantly focused on a tandem repeat polymorphism in exon III of *DRD4* because in vitro studies have shown that one variant (the 7-repeat allele) produces a blunted response to dopamine [25,26]. Faraone et al [8] conducted a meta-analysis of the 7-repeat allele of the exon III polymorphism and found statistically significant association with ADHD in both case-control (odds ratio=1.45 (95% CI 1.27-1.65)) and family based OR=1.16 (95% CI 1.03-1.31) studies. Li et al [17] reported a pooled OR of 1.34 (1.23-1.45) in 33 studies.

Not included in these meta-analyses of the exon III *DRD4* 48-bp VNTR were a prospective follow-up study of German children in which the 7-repeat *DRD4* allele was associated with increased incidence and persistence of ADHD in boys up to 11 years of age [27], a positive association with the 6 and 7 repeat alleles in a sample of 44 Indian ADHD trios (RR=1.81; $p=0.03$) [28], and a negative association in 126 Korean ADHD families ($p=0.67$) [29]. Carrasco et al [30] also failed to document an association with the 7 repeat allele in a small case-control study of 26 Chilean children with ADHD, but found a significant interaction with this *DRD4* marker and the dopamine transporter gene suggesting that children with the risk alleles at both loci are at greater risk of ADHD. In the large and comprehensive IMAGE project, the association with this VNTR and ADHD was not statistically significant ($p<0.09$) but the odds ratio (1.18) was very close to that observed in meta-analyses.

A small number of studies have assessed other *DRD4* polymorphisms; however, these data have not been conclusive. McCracken et al. [31,32] found an association between ADHD and a 5' 120-bp repeat 1.2 kb upstream of the initiation codon. However, Barr et al [33], Todd et al [34], Brookes et al [35], and Bhaduri et al [36] found no association between ADHD and this marker. Significant evidence of association was found by Arcos-Burgos et al [12], but only with the 5' 120-bp marker included with the exon III 48-bp 7-repeat allele in haplotype analysis.

Barr et al [33] found no association between ADHD and two SNPs in the promoter region (rs747302 and rs1800955), but Lowe et al [37] observed a significant over transmission of the rs1800955-A allele and a trend towards association with the rs747302-C allele. Brookes et al [38] did not genotype these SNPs in the IMAGE project, but observed nominal association with a SNP (rs9195457) for which the LD structure with previously associated SNPs could not be determined.

Although it has been suggested that the *DRD4* gene may be particularly relevant to symptoms of inattention, the literature suggests that this may not be so. Rowe et al.[39] found that fathers of ADHD children with the 7-repeat allele had higher levels of retrospectively reported inattention symptoms, and Levitan et al. [40] found an association between this allele and greater self-reported childhood inattention in women with seasonal affective disorder. However, Todd et al [41] found no association with the exon III 48-bp VNTR and any ADHD symptom profiles or DSM-IV subtypes in pooled analysis of 2,090 children. Similarly, Mill et al [42] found no association with the 7-repeat allele and a quantitative measure of ADHD symptom profiles in 329 pairs of male twins ascertained in England and Wales. Although the 7-repeat allele was not present in a sample of Korean ADHD children, Kim et al [29] reported no variation of inattentive symptoms with the number of repeats but rather observed a greater severity of hyperactive/impulsive symptoms in subjects with a 5-repeat allele.

Furthermore, on neuropsychological measures of attention, subjects possessing the 7-repeat allele have demonstrated significantly better attention than subjects with fewer repeats [43-45] or demonstrated no difference on similar measures of attention [46]. However, Bellgrove et al [45] found that the rs747302-A allele was associated with sustained attention deficits while the 7-repeat allele of the exon III VNTR was associated with improved performance. Thus, they conclude that such risk alleles have dissociable effects on cognition in ADHD children [45].

Two studies have provided evidence documenting strength of a *DRD4*-ADHD relationship relative to other phenotypes hypothesized to also be associated with *DRD4*: autism [47] and a novelty seeking temperament [48]. Grady et al [47] found no evidence of an over-representation of rare *DRD4* variants in a sample of children with autism relative to geographically matched controls, while a sample of ADHD children had a four-fold increase in novel alleles compare to geographically matched controls. Furthermore, Lynn et al [48] examined the relationship between ADHD, novelty seeking and the exon III *DRD4* 48-bp VNTR and found independent associations with ADHD/novelty seeking, and ADHD/*DRD4*, but not with *DRD4*/novelty seeking. Although not conclusive these studies suggest that the association between ADHD and *DRD4* is relatively specific (i.e. relative to autism) and not confounded by common comorbid behaviors (i.e. increased novelty seeking).

The Dopamine 5 receptor (*DRD5*)

The most widely studied polymorphism for *DRD5* has been a dinucleotide repeat that maps approximately 18.5 kb 5' to the transcription start site [49]. Meta-analysis of 14 independent family-based studies suggested a significant association of the 148-bp allele with ADHD (OR=1.2; 95% CI 1.1-1.4) [19] that was confirmed in updated analyses conducted by Li et al [17] (OR=1.3; 95% CI 1.2-1.5). Not included in these meta-analyses is a study by Mill et al [42] examining quantitative measures of ADHD symptoms in 329 pairs of male twins ascertained in England and Wales. Again, the 148-bp allele was statistically significantly associated with ADHD, but unfortunately the direction of effect was in the opposite direction: the risk allele was associated with lower hyperactivity scores [42].

Other markers within *DRD5* have also been found to be associated with ADHD. Hawi et al. [49] studied two additional 5' microsatellite markers and a SNP in the 3' UTR. The 3' SNP was associated with ADHD (relative risk = 1.6) and haplotype analyses showed an association with ADHD and a two-marker haplotype of one of the 5' microsatellite markers (D4S1582) and the dinucleotide repeat (*DRD5-PCR1*) ($p=0.000107$), a two-marker haplotype comprising *DRD5-PCR1* and the 3' SNP ($p=0.0099$), and a haplotype comprised of all three of these markers ($p=0.0013$).

The Dopamine Transporter Gene (*DAT*, *SLC6A3*)

There are several reasons that *SLC6A3* has been considered a suitable candidate for ADHD. Stimulant medications, which are efficacious in treating ADHD, block the dopamine transporter as one mechanism of action for achieving their therapeutic effects [50]. In mice, eliminating *SLC6A3* gene function leads to two features suggestive of ADHD: hyperactivity and deficits in inhibitory behavior. Treating these "knockout" mice with stimulants reduces their hyperactivity [51,52].

Using a family-based association study, Cook et al. [53] first reported an association between ADHD and the 10-repeat allele of the 3'UTR VNTR. Our previous meta-analysis of family-based studies resulted in a small but significant odds ratio (1.13, 95% CI 1.03-1.24), however Li et al [17] updated this work and found no evidence of association with ADHD and the 10-repeat allele in family-based studies (OR=1.04, 95% CI=0.99-1.14), as well as considerable

evidence of heterogeneity between studies ($p(Q) = 0.000001$). A subsequent meta-analysis of this gene found small but significant association with ADHD for family-based TDT studies ($OR = 1.17$, 95% $CI = 1.05-1.30$) [20]. The odd ratio for seven family-based HHRR studies was 1.5, but it was not significant. Although there were only six case-control studies, their combined odds ratio of 0.95 would seem to disconfirm the family-based studies [20].

Thus, the lack of consistent association with the 3' UTR VNTR suggests that this marker itself is not directly involved in the etiology of ADHD, but it may be tagging a proximate functional polymorphism in partial linkage disequilibrium (LD) with the 10-repeat allele. In an attempt to further refine the *SLC6A3* risk variant for ADHD, Brookes et al. [54] reported association with a haplotype comprised the 10-repeat allele in the 3'UTR and the 6-repeat allele of a 30-bp VNTR in intron 8. Of the four possible haplotype combinations of the two markers, only the 10-6 haplotype was associated with increased risk for ADHD in both populations. This finding was replicated by Brookes et al. [38] ($OR=1.19$, $p<0.06$) and Asherson et al. [55] in the second set of 383 ADHD probands from the IMAGE sample ($OR=1.27$, $p=0.002$). Bakker et al [56] failed to identify an overall association with this haplotype ($p=0.2$) or preferential over transmission of the 10-6 variant in 198 Dutch probands with ADHD.

However, evidence is emerging that environmental risk factors for ADHD might be important mediators of the risk for ADHD associated with *SLC6A3*. Brookes et al [54] also reported a gene-environment interaction suggesting that the risk for ADHD was increased only in the presence of the 10-6 *SLC6A3* haplotype when there was also exposure to maternal alcohol use during pregnancy. Although the 9-repeat allele was significantly over transmitted in the sample [57] utilized by Neuman et al [58], they documented an increased risk for the severe combined ADHD profile with both *SLC6A3* and the *DRD4* 7-repeat allele only in children who were exposed to maternal cigarette smoking during pregnancy. Similarly, Laucht et al [59] found that the 3'UTR 10-repeat allele, the intron 8 6-repeat allele, and the 10-6 haplotype were associated with ADHD symptoms only in families exposed to higher psychosocial adversity.

Dopamine Beta-Hydroxylase (DBH)

DBH is the primary enzyme responsible for conversion of dopamine to norepinephrine. Comings et al. [60,61] examined a TaqI restriction site polymorphism in intron 5 and found a significant association with the A1 allele and ADHD symptom scores in children with Tourette's Syndrome (TS) [61]. Smith et al. [62] subsequently replicated this association ($OR = 1.96$; 95% $CI: 1.01-3.79$) in ADHD subjects but Daly et al. [63] and Roman et al [64] found over-transmission of the A2 allele. Both also found that the association was stronger in combined-type ADHD cases but Daly et al [63] found that parental history of ADHD strengthened the association while Roman et al [64] found stronger evidence of association in those with no parental history of ADHD. In a Canadian study of 117 families with children with ADHD, Wigg et al. [65] reported a non-significant excess transmission of the A2 allele. Subsequently, a case-control study of Indian ADHD children [66] and both case-control and family-based analyses of persistent ADHD cases in Canada [67] have failed to document a significant association with this marker of DBH.

Other markers of *DBH* have also shown a lack of significant association with ADHD. Wigg et al [65] observed no evidence of linkage or association for the dinucleotide repeat polymorphism and an insertion/deletion polymorphism in the region 5' to the transcription start site (both of which had been associated with serum *DBH* levels). A G/T SNP in exon 5 of *DBH* was examined in 104 trios from the UK Payton et al. [68] and in 86 trios from Ireland [49] and showed no evidence of association. Hawi et al [69] also examined an EcoN1 restriction site polymorphism in exon 2 and an MspI polymorphism in intron 9 and found association for only a haplotype comprised of allele 1 of the exon 2 polymorphism and A2 of the TaqI polymorphism. A -1021C>T polymorphism in the 5' flanking region of *DBH* has been shown

to account for as much as 50% of plasma *DBH* activity and was associated with ADHD in the Han Chinese [70], but not in a sample of Indian ADHD children [66]. Finally, 33 SNPs were tagged for this gene in the IMAGE project, but there were no nominally significant associations with ADHD found [38].

Monoamine Oxidase A (MAO-A)

The *MAO-A* enzyme moderates levels of norepinephrine, dopamine, and serotonin, and *MAO-A* knockout mice display numerous abnormalities in these neurotransmitter systems [71]. A case-control study of a 30-bp pair tandem repeat in the promoter region in 129 Israeli ADHD subjects suggested association with ADHD and noted a particularly large effect in the subset of female cases ($n=19$) [72]. The 4 and 5 repeat alleles of this promoter-region VNTR were also significantly associated with ADHD in a sample of 133 Israeli families [72], but not in a similarly-sized family-based study by Lawson et al [73]. A CA-repeat microsatellite in intron 2 was associated with ADHD [74] in 82 Chinese, but this was not replicated in Caucasian samples [68,75].

Domschke et al [75] also examined a SNP in exon 8 (941G>T) and found association with the high activity G941T allele and with a haplotype containing the G941T allele, the 3-repeat allele of 30-bp VNTR and the 6-repeat of the CA microsatellite described above. Xu et al [76] replicated the association with G941T allele and the over-transmission of a haplotype contain the G941T allele and the shorter 3-repeat allele of the promoter VNTR in a Taiwanese sample. Five tagged SNPs for MAO-A were statistically significantly associated with ADHD in the IMAGE sample [38]. The 941G>T SNP was not included in that analysis but the region covered by the window of significant SNPs incorporated the location of this SNP.

The Dopamine D2 receptor (DRD2)

The *dopamine D2 receptor (DRD2)* has been less extensively studied in ADHD than *DRD4* and *DRD5*. Comings [77] compared 104 ADHD subjects (nearly all with comorbid Tourette's syndrome) to controls, and found a significant association with the TaqIA1 allele of *DRD2*, which they subsequently replicated [60]. This finding was replicated in a case-control sample of Czech boys with ADHD [78], but not in a sample of Korean alcoholics with and without ADHD [79].

Family-based studies of *DRD2* have been uniformly negative, however. Rowe et al. [80] examined 164 ADHD children from 125 families, and found no excess transmission of the TaqIA1 allele. A subsequent study of Taiwanese families likewise found no association [81]. Kirley et al. [82] examined two polymorphisms in 118 ADHD children and their families. No significant associations were identified, though they reported a trend towards significance ($p=0.07$) for the Ser311 polymorphism when paternally transmitted. Finally, the IMAGE project examined 23 tag SNPs and found no nominally significant association with ADHD.

The Dopamine D3 receptor (DRD3)

Barr et al. [83] examined a Ser9Gly exon 1 polymorphism and an intron 5 MspI restriction site polymorphism in 100 Canadian families but neither the individual loci nor haplotypes of the two were associated with ADHD. Negative results for the Ser9Gly polymorphism were also reported in a UK family-based study of 105 families [68] and a study of 39 families of ADHD adults [84]. Comings et al. [85] also found no evidence for association with ADHD and comorbid Tourette Syndrome. In a sample of 146 German patients referred for forensic evaluation [86], heterozygosity at this polymorphism was associated with higher impulsivity scores although this effect was only seen among those with a history of violence. Similarly, none of the 28 *DRD3* SNPs tagged for the IMAGE project were nominally significant [38].

Catechol-O-methyltransferase (COMT)

COMT catalyzes a major step in the degradation of dopamine, norepinephrine, and epinephrine. The most extensively studied marker for the *COMT* gene is the Val108Met polymorphism, which yields either a high- or low- activity form of *COMT* [87]. Cheuk et al [22] conducted a meta-analysis of this marker and found no evidence of association with ADHD in case-control studies (OR=0.95 (0.75-1.2), p=0.7) or family-based studies utilizing the TDT (OR=0.95 (0.84-1.09), p=0.5) or the HHRR (OR=1.02 (0.78-1.34), p=0.9). Reuter et al [88] found that higher symptom scores were associated with the MET/MET genotype in German adults who were healthy or diagnosed with eating or substance use disorders and Gothelf [89] documented a 5-fold increased risk for the MET allele in 55 subjects with velocardiofacial syndrome and comorbid ADHD relative to those without comorbid ADHD. The lack of significant results from the IMAGE project [90] is consistent with the negative meta-analysis conducted by Cheuk et al [22]. Although these association studies rule out a simple role for the Val108Met polymorphism in the etiology of ADHD, it is of note that *COMT* has been found to be highly upregulated in a rat model of ADHD caused by prenatal exposure to polychlorinated biphenyls [91].

Noradrenergic Receptors: ADRA2A, 2C and 1C

Three adrenergic receptors have been examined in ADHD. The *alpha-2A adrenergic receptor* (*ADRA2A*) has a promoter-region SNP (-1291 C>G) which has been examined in both case-control and family-based studies. Comings et al. [92] reported an association between genotypes at this SNP and ADHD symptom scores and that the G-1291C allele was associated with ADHD and oppositional defiant or conduct disorder symptoms while the C-1291G allele was associated with a spectrum of other conditions including panic attacks, obsessive compulsive disorder (OCD), addictions, affective, and schizoid symptoms. However, family-based studies failed to detect association with -1291C>G polymorphism and the diagnosis of ADHD [93-99]. The G-1291C allele of this marker has been shown to be associated with ADHD symptom scores, but the direction of effect has been inconsistent: some studies found association with only inattentive symptoms [100] while others found association with both inattentive and hyperactive symptoms [94,95]. In contrast, Wang et al [98] found no association with ADHD in a sample of Han Chinese but a trend toward lower ADHD symptom score in subjects homozygous for the G-1291C allele. Examination of other markers have been similarly inconsistent with the G-1291C allele being included in a significantly over-transmitted haplotype in a sample of 51 trios [95] while the C-1291G allele was included in a significant haplotype in sib-pair linkage study of 93 ADHD probands and 50 of their unaffected siblings [99].

While these results suggest either a weak or no association with ADHD and the 1291G>C polymorphism, they do not take heterogeneity in the presentation of ADHD into account. Schmitz et al [96] conducted a unique study of exclusively inattentive-type ADHD children and found a significant association with the G-1291C allele in case-control but not family-based analyses. Waldman et al [101] evaluated the moderating and mediating effects of executive function deficits on the association of *ADRA2A* and ADHD and found that association with ADHD was more robust in children with poorer cognitive performance. Although Stevenson et al [102] reported no overall association with *ADRA2A*, there was a significant over-transmission of the G-1291C allele in the sub-sample with a reading disability.

A dinucleotide repeat polymorphism located approximately 6 kb from the gene which codes for the *alpha-2C adrenergic receptor* (*ADRA2C*;) has also been examined in both case control and family-based analyses. Comings et al. [103] found an association between this polymorphism and ADHD symptom scores, but it was not significant after Bonferroni correction. Two subsequent family-based analyses showed no evidence of association [104,

105]. The former study also examined a C-to-T SNP in codon 492 of the *1C receptor* (*ADRA1C*) that changes cysteine to arginine but found no evidence of linkage [104]. In the IMAGE project, there was no nominally significant association with any of SNPs tagged for *ADRA2A* or *ADRA2C* [38].

The Norepinephrine Transporter (NET; *SLC6A2*)

SLC6A2 has been examined in ADHD because drugs that block the norepinephrine transporter are efficacious in treating ADHD [106]. Comings et al. [85] found evidence for association of a SNP in *SLC6A2* with ADHD symptoms. Subsequently, Barr et al. [107] examined 3 SNPs in *SLC6A2* (one in exon 9, intron 9 and intron 13, respectively) in 122 ADHD families and found no evidence of association for these loci or haplotypes comprising them. Others have found no association with SNPs in intron 7 or 9 [108] or with a restriction fragment length polymorphism in ADHD adults [109]. However, Xu et al [110] investigated 21 SNPs spanning the NET region in 180 cases and 334 controls and reported nominally significant association with rs3785157 that was later replicated by Bobb et al [111] with an additional significant association with rs998424. Although these SNPs were not found to be associated with ADHD in the IMAGE study [38], two of the 43 tagged SNPs (rs3785143 and rs11568324) for *SLC6A2* did reach nominal statistical significance. Finally, a novel promoter SNP has been shown to be possibly associated with ADHD in a set of 94 ADHD cases and 60 controls [112].

Association Studies of Serotonergic Genes

Serotonin receptors: *HTR1B* and *HTR2A*

Of the family-based association studies of a silent SNP (861G>C) in the gene coding for the *serotonin HTR1B receptor* [111,113-116], only the multi-site study by Hawi et al. [113] reached statistical significance suggesting over-transmission of the G861C allele. Smoller et al pooled data from [113-115] and identified statistically significant over-transmission of this allele (OR=1.35 (1.13-1.62), $p=0.009$) that strongly suggested paternal ($p=0.00005$) rather than maternal transmission ($p=0.2$) [115]. There was a weak trend suggesting over-transmission of the G681 allele in Li et al. [17] when examining primarily inattentive ADHD subjects separately. Smoller et al [115] also identified association with this ADHD subtype and a 6-SNP haplotype including the G681C allele and two promoter SNPs with functional effects on *HTR1B* expression. Heiser et al [116] identified no association with the G681C allele but examined only the combined ADHD subtype and did not assess for paternal transmission separately. The analysis of combined-type ADHD in the IMAGE project did not identify association with any of the tag SNPs selected [38].

The T102C, G1438A, and His452Tyr polymorphisms of the serotonin *HTR2A receptor* gene have also been examined for association with ADHD [113,116-121]. No association has been reported for the T102C and the G1438A SNPs for ADHD in [116,118,119,121]. Likewise Bobb et al [111] found no evidence of association with ADHD and any of the SNPs of the *HTR2A* gene examined in either case-control or family-based analyses. However, Levitan et al. [122] found an association with C102T allele and greater scores on a self-report measure of childhood ADHD in a sample of women with seasonal affective disorder and Li et al [120] found that the A1438G allele was associated with functional remission from ADHD in Han Chinese adolescents. A coding polymorphism in the *HTR2A receptor* gene (His452Tyr) was associated with ADHD in [117,121], but not in [113,116].

Li et al [123] found significant over-transmission of the C-759T/G-697C haplotype within the *HTR2C* gene, but no association was observed in Bobb et al [111] or in the IMAGE project [38]. Li et al have also reported significant under transmission of the C83097T/G83198A haplotype in the *HTR4* gene [124], but no association with markers in *HTR5A* and *HTR6*

[119] or HTR1D [125]. Genes for additional serotonin receptors (*HTR1E* and *HTR3B*) evaluated in the IMAGE project [38] have also failed to yield any significant association with ADHD.

Serotonin transporter (HTT, SLC6A4)

A 44-base pair insertion/deletion polymorphism (HTTLPR) in the promoter region of *SLC6A4* may be the most studied genetic marker in psychiatric genetics, with associations reported for a broad range of diagnoses and traits [126,127]. When the HTTLPR studies published by 2005 were combined [8], the pooled odds ratio for the long (L) allele was 1.31 (95% CI 1.09-1.59). Curran et al [128] found nominal evidence of over transmission of the L allele and strong evidence of association with a 4 SNP haplotype upstream that included the 5-HTTPR ins/del polymorphism. However, subsequent studies of this marker in 126 Korean ADHD families [129], 197 ADHD families from the UK [130], 196 Taiwanese ADHD families [130,131], 56 Indian ADHD families [132], 209 Canadian ADHD families [133], and 102 German ADHD families [116] have failed to identify an association with the HTTLPR. Li et al [134] found statistically significant over-transmission of the S (rather than the L) allele in 279 Han Chinese ADHD families.

A 17-bp VNTR in intron 2 of *SLC6A4* (STint2) was first associated with ADHD in a case-control study conducted by [118] with the 12-12 genotype being under-represented in cases than controls. Banerjee et al [132] found significant over-transmission of the 12 allele, but Heiser [116], Xu [130] and Kim et al [129] found no association and Li et al [134] found evidence of under-transmission of a haplotype with the HTTLPR L allele and the STint2 12 allele. The IMAGE project found no association for the tag SNPs examined [38] and Wigg et al [133] found no association with 2 functional *SLC6A4* polymorphisms (rs3813034 (T/G) and Ile425Val (A/G)) and ADHD.

Tryptophan Hydroxylase (TPH and TPH-2)

TPH is the rate-limiting enzyme in the synthesis of serotonin, and *TPH* polymorphisms have been associated with aggression and impulsivity [135]. Two family-based studies examined the *TPH* gene in ADHD. One study of 69 Han Chinese trios found no association with a SNP (A218C) in intron 7 [136]. A second study examined two SNPs among more than 350 Han Chinese youth with ADHD, with and without learning disability, and their families [137, 138]. Although neither SNP showed biased transmission individually, a haplotype composed of the A218 and G-6526 alleles appeared to be under-transmitted ($p=0.03$).

The gene for a second form of *TPH* (*TPH2*) located on chromosome 12q15 has also been studied. Walitza et al examined two SNPs located in the transcriptional control region of *TPH-2* (rs4570625 and rs11178997) a third located in intron 2 (rs4565946)). Tests of the transcriptional SNPs individually and in a 2-SNP haplotype were modestly associated with ADHD in the 225 affected children (103 families), but the intron 2 SNP was not associated. Sheehan et al [139] studied 8 additional SNPs in 179 ADHD families and found statistically significant evidence of association with the rs1843809-T allele ($p=0.0006$), the rs1386497-A allele ($p=0.048$), and a trend suggesting association with the rs1386493-C allele ($p=0.09$). In the IMAGE project rs1843809 and rs1386497 were also significantly associated with ADHD, but the alleles implicated in Sheehan et al [139] were not [38]. Brookes et al also reported an association with rs1007023 which was in perfect LD with rs1386497 from Sheehan et al [38]. However, Brookes et al did not replicate the finding reported by Walitza et al [140] and Sheehan et al was not able to replicate their earlier findings in a smaller sample of 63 ADHD trios [141].

Association Studies of Other Candidate Genes

Synaptosomal Associated Protein of 25kD (SNAP25)

SNAP25 is a 206 amino acid protein found on chromosome 20p12. The gene product is a presynaptic plasma membrane protein involved in the regulation of neurotransmitter release. Its relevance to ADHD was motivated by the coloboma mouse, which has a hemizygous two centimorgan deletion of a segment on chromosome 2q, including the gene encoding SNAP-25. The coloboma mutation leads to spontaneous hyperactivity, delays in achieving complex neonatal motor abilities, deficits in hippocampal physiology, which may contribute to learning deficiencies, and deficits in Ca²⁺-dependent dopamine release in dorsal striatum [142]. Four family-based studies of *SNAP25* examined two SNPs (1069T>C and 1065T>G) separated by four base pairs at the 3' end of the gene [143-147]. Meta-analysis of these studies showed significant evidence for an association with ADHD and T1065G (OR=1.19, 95% CI 1.03-1.38). Feng et al [148] examined 12 SNPs in two independent samples of ADHD families and found significant over-transmission of the rs66039806-C, rs362549-A, rs362987-A, and the rs362998-C alleles in families from Toronto, but not California. The IMAGE analysis of pooled data did not test these specific markers, but did demonstrate nominally statistically significant association with *SNAP-25* and other markers (rs363020 and rs362567) [38] the 5'UTR. Kim et al [149] examined the previously implicated SNPs and five additional SNPs (rs6077699, rs363006, rs362549, rs362987, rs362998) but found no evidence of association with ADHD in tests of individual markers or haplotypes. However, a combined TDT analysis of pooled data was modestly significant for rs3746544-T (P = 0.048) and rs6077690-T (P = 0.031). Stratification by psychiatric comorbidity further suggested that subjects with ADHD and comorbid depression may demonstrate stronger association with SNPs in *SNAP-25* [149].

Acetylcholine Receptors: *CHRNA4*

The nicotinic acetylcholine receptors are ligand-gated ion channels composed of five subunits, one of which is the alpha-4 subunit (*CHRNA4*), which has been examined in several studies in ADHD. Comings et al. [150] found evidence of association with an intron 1 dinucleotide repeat polymorphism of the *CHRNA4* gene and ADHD symptoms in a case-control study of children with Tourette Syndrome, but Kent et al. [151] found no significant evidence of association with a CfoI restriction site polymorphism in exon 5 in a study of 68 trios. Todd et al. [152] examined seven SNPs encompassing exons 2 and 5 as well as haplotypes of these markers and found significant association for inattentive ADHD with an intronic SNP (G/A) near the exon/intron boundary at the 3' end of exon 2. Subsequent examination of *CHRNA4* in samples of combined-type ADHD cases have not replicated this association [38,111] although the IMAGE project did report association with a SNP in the 5' flanking region. Lee et al [153] failed to replicate the association with SNPs from Todd et al [152] or the IMAGE study [38] for either categorical ADHD diagnosis or symptom profile scores. In contrast to Todd et al [152], Lee et al [153] found over-transmission of the rs2273505-G and rs3787141-T alleles with the combined ADHD subtype and hyperactivity-impulsivity scores.

Glutamate receptors

The *GRIN2A* gene, which encodes a subunit of the N-methyl D-aspartate receptor has been examined in family-based studies of ADHD. Glutamate and the NMDA receptor have been implicated in cognition in both animal and human studies; the *GRIN2A* gene is an appealing positional candidate gene as well, located under a linkage peak at 16p13 previously associated with ADHD [10]. In a family-based analysis of 238 families, a SNP in exon 5 (*Grin2a_5*) was significantly associated with ADHD (p=0.01); haplotypes including additional SNPs were more weakly associated [154] However, among 183 families, no evidence for association was identified for this SNP (p=0.74) or three others [155].

Brain-derived neurotrophic factor (BDNF)

BDNF is a protein that supports survival of central nervous system neurons and stimulates growth and differentiation of developing neurons. A polymorphism producing an amino acid substitution (valine to methionine) at codon 66 of the *BDNF* may impact intracellular trafficking and activity-dependent secretion of *BDNF* [156]. Kent et al [157] found over transmission of the Val66 allele and that this was accounted for by paternal ($p=0.0005$) rather than maternal ($p=1.0$) transmission in 341 Caucasian ADHD probands and their family members. However, Xu et al [158] failed to replicate these associations with Val66 in samples from the UK or Taiwan. Xu et al also examined the 270C>T SNP in the 5'-noncoding region of intron1 and found significant over transmission of the C720T allele in Taiwanese, but not UK, ADHD families [158]. Twenty SNPs in the *BDNF* gene were tagged for the IMAGE project, but none were statistically significantly associated with ADHD [38].

Genome-wide Association Studies

To date, there have been two genome-wide association studies (GWAS) of ADHD. The International ADHD Genetics (IMAGE) project examined 909 trio families (two parents and one ADHD child) using 438,784 tagging SNPs designed to be in high linkage disequilibrium with all untyped SNPs in the genome. No finding achieved genome-wide significance (i.e., a P -value of $<5 \times 10^{-8}$) in the primary analysis of the ADHD diagnosis [159] but this analysis and several exploratory analyses implicated some novel genes that require further study [160, 161]. Of interest, one of the exploratory analyses implicated the *CDH13* gene, which was also implicated in a second GWAS of 343 ADHD adults and 250 controls [162]. *CDH13* lies under the linkage peak implicated in the meta-analysis of ADHD linkage studies discussed.

The IMAGE study also explored the existing candidate genes from the ADHD literature, to place the potential effects in context. They examined two sets of candidates. The first set comprised genes that showed significant association with ADHD in meta-analyses performed by Faraone et al. [8]. These are *SNAP25*, *DRD4*, *SLC6A3*, *HTR1B*, *SLC6A4*, and *DBH*. The second set consisted of genes that had been nominated by the study investigators as good candidates for ADHD [38]. These were: *NR4A2*, *PER2*, *SLC6A1*, *DRD3*, *SLC9A9*, *HES1*, *ADRA2C*, *ADRB2*, *ADRA1B*, *DRD1*, *HTR1E*, *DDC*, *STX1A*, *ADRA1A*, *NFIL3*, *ADRA2A*, *ADRB1*, *SLC18A2*, *TPH1*, *BDNF*, *FADS1*, *FADS2*, *ADRBK1*, *ARRB1*, *DRD2*, *HTR3B*, *TPH2*, *SYT1*, *HTR2A*, *SLC6A2*, *ARRB2*, *PER1*, *PNMT*, *CHRNA4*, *COMT*, *ADRBK2*, *CSNK1E*, *MAOA*, *MAOB*, and *HTR2C*. Although none of the SNPs in these achieved genomewide significance, when the SNPs in these genes were analyzed as a group, the results suggested that they were weakly associated with ADHD [159].

Discussion

Although twin studies demonstrate that ADHD is a highly heritable condition, molecular genetic studies suggest that the genetic architecture of ADHD is complex. The handful of genome-wide scans that have been conducted thus far show divergent findings and are, therefore, not conclusive. Similarly, many of the candidate genes reviewed here (i.e. *DBH*, *MAOA*, *SLC6A2*, *TPH-2*, *SLC6A4*, *CHRNA4*, *GRIN2A*) are theoretically compelling from a neurobiological systems perspective, but available data are sparse and inconsistent. However, candidate gene studies of ADHD have produced substantial evidence implicating several genes in the etiology of the disorder. The literature published since recent meta-analyses is particularly supportive for a role of the genes coding for *DRD4*, *DRD5*, *SLC6A3*, *SNAP-25*, and *HTR1B* in the etiology of ADHD.

Yet, even these associations are small and consistent with the idea that the genetic vulnerability to ADHD is mediated by many genes of small effect. These small effects emphasize the need

for future candidate gene studies to implement strategies that will provide enough statistical power to detect such small effects. One such strategy, examination of refined phenotypes that may reduce heterogeneity, is beginning to bear fruit but more research is needed to extend the work focused on ADHD subtypes (e.g. inattentive subtype and *HTR1B*); comorbid psychopathology or cognitive impairment (e.g. depression and *SNAP-25*, reading disability and *ADRA2A*), and gene-environment interactions (e.g. prenatal or psychosocial risk factors for ADHD and *SLC6A3*). It is also possible that ADHD genetics research will benefit from the study of endophenotypes such as neuropsychological functioning or brain imaging [163–165]. The ongoing efforts to develop larger collaborative studies with adequate sizes for genome-wide association studies will also be critical in understanding the molecular genetics of ADHD.

Acknowledgments

The chapter was adapted from: Mick, E. & Faraone, S. V. (2008). Genetics of attention deficit hyperactivity disorder. *Child Adolesc Psychiatr Clin N Am* 17, 261–84, vii–viii.

References

1. Faraone SV, et al. The Worldwide Prevalence of ADHD: Is it an American Condition? *World Psychiatry* 2003;2(2):104–113. [PubMed: 16946911]
2. Kessler RC, et al. The prevalence and correlates of adult ADHD in the United States: Results from the national comorbidity survey replication. *American Journal of Psychiatry* 2006;163(4):716–723. [PubMed: 16585449]
3. Faraone SV, Biederman J. Nature, nurture, and attention deficit hyperactivity disorder. *Developmental Review* 2000;20:568–581.
4. Faraone SV, et al. Diagnosing Adult attention deficit hyperactivity disorder: Are Late Onset and Subthreshold Diagnoses Valid? *American Journal of Psychiatry* 2006;163(10):1720–9. [PubMed: 17012682]
5. Sprich S, et al. Adoptive and biological families of children and adolescents with ADHD. *Journal of the American Academy of Child and Adolescent Psychiatry* 2000;39(11):1432–7. [PubMed: 11068899]
6. Cantwell DP. Genetics of hyperactivity. *Journal of Child Psychology and Psychiatry* 1975;16:261–264. [PubMed: 1171894]
7. Morrison JR, Stewart MA. The psychiatric status of the legal families of adopted hyperactive children. *Archives of General Psychiatry* 1973;28(June):888–891. [PubMed: 4707995]
8. Faraone SV, et al. Molecular genetics of attention-deficit/hyperactivity disorder. *Biol Psychiatry* 2005;57(11):1313–23. [PubMed: 15950004]
9. Fisher SE, et al. A genomewide scan for loci involved in attention-deficit/hyperactivity disorder. *Am J Hum Genet* 2002;70(5):1183–96. [PubMed: 11923911]
10. Smalley SL, et al. Genetic Linkage of Attention-Deficit/Hyperactivity Disorder on Chromosome 16p13, in a Region Implicated in Autism. *Am J Hum Genet* 2002;71(4):959–63. [PubMed: 12187510]
11. Bakker SC, et al. A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q. *Am J Hum Genet* 2003;72(5):1251–1260. [PubMed: 12679898]
12. Arcos-Burgos M, et al. Pedigree disequilibrium test (PDT) replicates association and linkage between DRD4 and ADHD in multigenerational and extended pedigrees from a genetic isolate. *Mol Psychiatry* 2004;9(3):252–9. [PubMed: 15094785]
13. Ogdie MN, et al. Pooled genome-wide linkage data on 424 ADHD ASPs suggests genetic heterogeneity and a common risk locus at 5p13. *Mol Psychiatry* 2006;11(1):5–8. [PubMed: 16205734]
14. Hebebrand J, et al. A genome-wide scan for attention-deficit/hyperactivity disorder in 155 german sib-pairs. *Mol Psychiatry* 2006;11(2):196–205. [PubMed: 16222334]

15. Lander E, Kruglyak L. Genetic dissection of complex traits: Guidelines for interpreting and reporting linkage results. *Nature Genetics* 1995;11:241–247. [PubMed: 7581446]
16. Zhou K, et al. Meta-analysis of genome-wide linkage scans of attention deficit hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet* 2008;147B(8):1392–1398. [PubMed: 18988193]
17. Li D, et al. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). *Hum Mol Genet* 2006;15(14):2276–84. [PubMed: 16774975]
18. Faraone SV, et al. Meta-analysis of the association between the 7-repeat allele of the dopamine d(4) receptor gene and attention deficit hyperactivity disorder. *American Journal of Psychiatry* 2001;158(7):1052–7. [PubMed: 11431226]
19. Lowe N, et al. Joint Analysis Of DRD5 Marker Concludes Association with ADHD Confined to the Predominantly Inattentive and Combined Subtypes. *American Journal of Human Genetics* 2004;74(2):348–356. [PubMed: 14732906]
20. Yang B, et al. A meta-analysis of association studies between the 10-repeat allele of a VNTR polymorphism in the 3'-UTR of dopamine transporter gene and attention deficit hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet* 2007;144B(4):541–550. [PubMed: 17440978]
21. Purper-Ouakil D, et al. Meta-analysis of family-based association studies between the dopamine transporter gene and attention deficit hyperactivity disorder. *Psychiatr Genet* 2005;15(1):53–9. [PubMed: 15722958]
22. Cheuk DK, Wong V. Meta-analysis of Association Between a Catechol-O-Methyltransferase Gene Polymorphism and Attention Deficit Hyperactivity Disorder. *Behav Genet*. 2006
23. Lanau F, et al. Epinephrine and norepinephrine act as potent agonists at the recombinant human dopamine D4 receptor. *Journal of Neurochemistry* 1997;68(2):804–812. [PubMed: 9003072]
24. Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. *Biological Psychiatry* 1998;44(10):951–958. [PubMed: 9821559]
25. Van Tol HH, et al. Multiple dopamine D4 receptor variants in the human population. *Nature* 1992;358(6382):149–52. [PubMed: 1319557]
26. Asghari V, et al. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. *Journal of Neurochemistry* 1995;65(3):1157–1165. [PubMed: 7643093]
27. El-Faddagh M, et al. Association of dopamine D4 receptor (DRD4) gene with attention-deficit/hyperactivity disorder (ADHD) in a high-risk community sample: a longitudinal study from birth to 11 years of age. *J Neural Transm* 2004;111(7):883–9. [PubMed: 15206004]
28. Bhaduri N, et al. Analysis of polymorphisms in the dopamine Beta hydroxylase gene: association with attention deficit hyperactivity disorder in Indian children. *Indian Pediatr* 2005;42(2):123–9. [PubMed: 15767706]
29. Kim YS, et al. Family-based association study of DAT1 and DRD4 polymorphism in Korean children with ADHD. *Neurosci Lett* 2005;390(3):176–81. [PubMed: 16165273]
30. Carrasco X, et al. Genotypic interaction between DRD4 and DAT1 loci is a high risk factor for attention-deficit/hyperactivity disorder in Chilean families. *Am J Med Genet B Neuropsychiatr Genet* 2006;141(1):51–4. [PubMed: 16342279]
31. McCracken JT, et al. Evidence for linkage of a tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4) with attention deficit hyperactivity disorder (ADHD). *Mol Psychiatry* 2000;5(5):531–6. [PubMed: 11032387]
32. Kustanovich V, et al. Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in ADHD: confirmation of association of ADHD with DRD4 and DRD5. *Mol Psychiatry*. 2003
33. Barr CL, et al. 5'-untranslated region of the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. *American Journal of Medical Genetics* 2001;105(1):84–90. [PubMed: 11425008]
34. Todd RD, et al. Lack of association of dopamine D4 receptor gene polymorphisms with ADHD subtypes in a population sample of twins. *American Journal of Medical Genetics* 2001;105(5):432–8. [PubMed: 11449395]
35. Brookes KJ, et al. No evidence for the association of DRD4 with ADHD in a Taiwanese population within-family study. *BMC Med Genet* 2005;6:31. [PubMed: 16143039]

36. Bhaduri N, et al. Association of dopamine D4 receptor (DRD4) polymorphisms with attention deficit hyperactivity disorder in Indian population. *Am J Med Genet B Neuropsychiatr Genet* 2006;141B(1):61–66. [PubMed: 16331654]
37. Lowe N, et al. Multiple marker analysis at the promoter region of the DRD4 gene and ADHD: evidence of linkage and association with the SNP -616. *Am J Med Genet* 2004;131B(1):33–7. [PubMed: 15389764]
38. Brookes K, et al. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. *Mol Psychiatry*. 2006
39. Rowe DC, et al. Two dopamine genes related to reports of childhood retrospective inattention and conduct disorder symptoms. *Molecular Psychiatry* 2001;6(4):429–33. [PubMed: 11443528]
40. Levitan RD, et al. Childhood inattention and dysphoria and adult obesity associated with the dopamine D4 receptor gene in overeating women with seasonal affective disorder. *Neuropsychopharmacology* 2004;29(1):179–86. [PubMed: 14560322]
41. Todd RD, et al. Collaborative analysis of DRD4 and DAT genotypes in population-defined ADHD subtypes. *J Child Psychol Psychiatry* 2005;46(10):1067–73. [PubMed: 16178930]
42. Mill J, et al. Quantitative trait locus analysis of candidate gene alleles associated with attention deficit hyperactivity disorder (ADHD) in five genes: DRD4, DAT1, DRD5, SNAP-25, and 5HT1B. *Am J Med Genet B Neuropsychiatr Genet* 2005;133B(1):68–73. [PubMed: 15578613]
43. Swanson J, et al. Attention deficit/hyperactivity disorder children with a 7-repeat allele of the dopamine receptor D4 gene have extreme behavior but normal performance on critical neuropsychological tests of attention. *Proceedings of the National Academy of Sciences of the United States of America* 2000;97(9):4754–9. [PubMed: 10781080]
44. Manor I, et al. The short DRD4 repeats confer risk to attention deficit hyperactivity disorder in a family-based design and impair performance on a continuous performance test (TOVA). *Mol Psychiatry* 2002;7(7):790–4. [PubMed: 12192625]
45. Bellgrove MA, et al. DRD4 gene variants and sustained attention in attention deficit hyperactivity disorder (ADHD): Effects of associated alleles at the VNTR and -521 SNP. *Am J Med Genet B Neuropsychiatr Genet* 2005;136(1):81–6. [PubMed: 15909295]
46. Langley K, et al. Association of the dopamine D4 receptor gene 7-repeat allele with neuropsychological test performance of children with ADHD. *Am J Psychiatry* 2004;161(1):133–138. [PubMed: 14702261]
47. Grady DL, et al. Sequence variants of the DRD4 gene in autism: further evidence that rare DRD4 7R haplotypes are ADHD specific. *Am J Med Genet B Neuropsychiatr Genet* 2005;136(1):33–5. [PubMed: 15892149]
48. Lynn DE, et al. Temperament and character profiles and the dopamine d4 receptor gene in ADHD. *Am J Psychiatry* 2005;162(5):906–13. [PubMed: 15863792]
49. Hawi Z, et al. Linkage disequilibrium mapping at DAT1, DRD5 and DBH narrows the search for ADHD susceptibility alleles at these loci. *Mol Psychiatry* 2003;8(3):299–308. [PubMed: 12660802]
50. Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention deficit hyperactivity disorder. *Child and Adolescent Psychiatric Clinics of North America* 2000;9(1):77–97. [PubMed: 10674191]
51. Giros B, et al. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. *Nature* 1996;379(6566):606–12. [PubMed: 8628395]
52. Gainetdinov RR, et al. Role of Serotonin in the Paradoxical Calming Effect of Psychostimulants on Hyperactivity. *Science* 1999;283:397–402. [PubMed: 9888856]
53. Cook EH, et al. Association of attention deficit disorder and the dopamine transporter gene. *American Journal of Human Genetics* 1995;56:993–998. [PubMed: 7717410]
54. Brookes KJ, et al. A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. *Arch Gen Psychiatry* 2006;63(1):74–81. [PubMed: 16389200]
55. Asherson P, et al. Confirmation that a specific haplotype of the dopamine transporter gene is associated with combined-type ADHD. *Am J Psychiatry* 2007;164(4):674–7. [PubMed: 17403983]
56. Bakker SC, et al. DAT1, DRD4, and DRD5 polymorphisms are not associated with ADHD in Dutch families. *Am J Med Genet B Neuropsychiatr Genet* 2005;132(1):50–2. [PubMed: 15389755]

57. Todd RD. Neural development is regulated by classical neurotransmitters: Dopamine D2 receptor stimulation enhances neurite outgrowth. *Biological Psychiatry* 1992;31:794–807. [PubMed: 1643194]
58. Neuman RJ, et al. Prenatal smoking exposure and dopaminergic genotypes interact to cause a severe ADHD subtype. *Biol Psychiatry* 2007;61(12):1320–8. [PubMed: 17157268]
59. Laucht M, et al. Interacting effects of the dopamine transporter gene and psychosocial adversity on attention-deficit/hyperactivity disorder symptoms among 15-year-olds from a high-risk community sample. *Arch Gen Psychiatry* 2007;64(5):585–90. [PubMed: 17485610]
60. Comings DE, Muhleman D, Gysin R. Dopamine D2 receptors (DRD2) gene and susceptibility to posttraumatic stress disorder: A study and replication. *Society of Biological Psychiatry* 1996;40:368–372.
61. Comings DE, et al. Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct and oppositional defiant disorder: The additive and subtractive effect of the three dopaminergic genes - DRD2, D β H and DAT1. *American Journal of Medical Genetics (Neuropsychiatric Genetics)* 1996;67:264–288. [PubMed: 8725745]
62. Smith KM, et al. Association of the dopamine beta hydroxylase gene with attention deficit hyperactivity disorder: Genetic analysis of the Milwaukee longitudinal study. *Am J Med Genet* 2003;119B(1):77–85. [PubMed: 12707943]
63. Daly G, et al. Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. *Molecular Psychiatry* 1999;4:192–196. [PubMed: 10208453]
64. Roman T, et al. Further evidence for the association between attention-deficit/hyperactivity disorder and the dopamine-beta-hydroxylase gene. *Am J Med Genet* 2002;114(2):154–158. [PubMed: 11857576]
65. Wigg K, et al. Attention deficit hyperactivity disorder and the gene for dopamine Beta-hydroxylase. *Am J Psychiatry* 2002;159(6):1046–8. [PubMed: 12042196]
66. Bhaduri N, Mukhopadhyay K. Lack of significant association between -1021C-->T polymorphism in the dopamine beta hydroxylase gene and attention deficit hyperactivity disorder. *Neurosci Lett* 2006;402(12):12–6. [PubMed: 16616989]
67. Inkster B, et al. Linkage disequilibrium analysis of the dopamine beta-hydroxylase gene in persistent attention deficit hyperactivity disorder. *Psychiatr Genet* 2004;14(2):117–120. [PubMed: 15167700]
68. Payton A, et al. Examining for association between candidate gene polymorphisms in the dopamine pathway and attention-deficit hyperactivity disorder: A family- based study. *American Journal of Medical Genetics* 2001;105(5):464–70. [PubMed: 11449400]
69. Hawi Z, et al. Dopa decarboxylase gene polymorphisms and attention deficit hyperactivity disorder (ADHD): no evidence for association in the Irish population. *Molecular Psychiatry* 2001;6(4):420–4. [PubMed: 11443526]
70. Zhang HB, et al. [Association between dopamine beta hydroxylase gene and attention deficit hyperactivity disorder complicated with disruptive behavior disorder]. *Zhonghua Er Ke Za Zhi* 2005;43(1):26–30. [PubMed: 15796803]
71. Cases O, et al. Plasma membrane transporters of serotonin, dopamine, and norepinephrine mediate serotonin accumulation in atypical locations in the developing brain of monoamine oxidase A knock-outs. *J Neurosci* 1998;18(17):6914–27. [PubMed: 9712661]
72. Manor I, et al. Family-based and association studies of monoamine oxidase A and attention deficit hyperactivity disorder (ADHD): preferential transmission of the long promoter-region repeat and its association with impaired performance on a continuous performance test (TOVA). *Mol Psychiatry* 2002;7(6):626–32. [PubMed: 12140786]
73. Lawson DC, et al. Association analysis of monoamine oxidase A and attention deficit hyperactivity disorder. *Am J Med Genet* 2003;116B(1):84–9. [PubMed: 12497620]
74. Jiang S, et al. Linkage studies between attention-deficit hyperactivity disorder and the monoamine oxidase genes. *Am J Med Genet* 2001;105(8):783–8. [PubMed: 11803531]
75. Domschke K, et al. Association analysis of the monoamine oxidase A and B genes with attention deficit hyperactivity disorder (ADHD) in an Irish sample: Preferential transmission of the MAO-A

- 941G allele to affected children. *Am J Med Genet B Neuropsychiatr Genet* 2005;134B(1):110–114. [PubMed: 15717295]
76. Xu X, et al. Association study between the monoamine oxidase A gene and attention deficit hyperactivity disorder in Taiwanese samples. *BMC Psychiatry* 2007;7(1):10. [PubMed: 17328795]
 77. Comings DE, et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. *Journal of the American Medical Association* 1991;266(13):1793–1800. [PubMed: 1832466]
 78. Sery O, et al. Polymorphism of DRD2 gene and ADHD. *Neuro Endocrinol Lett* 2006;27(12)
 79. Kim JW, et al. Clinical and genetic characteristics of Korean male alcoholics with and without attention deficit hyperactivity disorder. *Alcohol Alcohol* 2006;41(4):407–11. [PubMed: 16679343]
 80. Rowe DC, et al. The DRD2 TaqI polymorphism and symptoms of attention deficit hyperactivity disorder. *Mol Psychiatry* 1999;4(6):580–6. [PubMed: 10578241]
 81. Huang YS, et al. A family-based association study of attention-deficit hyperactivity disorder and dopamine D2 receptor TaqI A alleles. *Chang Gung Med J* 2003;26(12):897–903. [PubMed: 15008324]
 82. Kirley A, et al. Dopaminergic system genes in ADHD: toward a biological hypothesis. *Neuropsychopharmacology* 2002;27(4):607–19. [PubMed: 12377397]
 83. Barr CL, et al. Linkage study of two polymorphisms at the dopamine D3 receptor gene and attention-deficit hyperactivity disorder. *American Journal of Medical Genetics* 2000;96(1):114–117. [PubMed: 10686563]
 84. Muglia P, Jain U, Kennedy JL. A transmission disequilibrium test of the Ser9/Gly dopamine D3 receptor gene polymorphism in adult attention-deficit hyperactivity disorder. *Behav Brain Res* 2002;130(12):91–5. [PubMed: 11864723]
 85. Comings DE, et al. Comparison of the role of dopamine, serotonin, and noradrenaline genes in ADHD, ODD and conduct disorder: multivariate regression analysis of 20 genes. *Clinical Genetics* 2000;57(3):178–96. [PubMed: 10782925]
 86. Retz W, et al. Dopamine D3 receptor gene polymorphism and violent behavior: relation to impulsiveness and ADHD-related psychopathology. *J Neural Transm* 2003;110(5):561–72. [PubMed: 12721816]
 87. Syvanen AC, et al. Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. *Pharmacogenetics* 1997;7(1):65–71. [PubMed: 9110364]
 88. Reuter M, Kirsch P, Hennig J. Inferring candidate genes for Attention Deficit Hyperactivity Disorder (ADHD) assessed by the World Health Organization Adult ADHD Self-Report Scale (ASRS). *J Neural Transm* 2006;113(7):929–38. [PubMed: 16362639]
 89. Gothelf D, et al. Association of the low-activity COMT 158 Met allele with ADHD and OCD in subjects with velocardiofacial syndrome. *Int J Neuropsychopharmacol* 2007;10(3):301–8. [PubMed: 16734939]
 90. Brookes KJ, et al. DNA pooling analysis of ADHD and genes regulating vesicle release of neurotransmitters. *Am J Med Genet B Neuropsychiatr Genet*. 2005
 91. Dasbanerjee T, et al. A comparison of molecular alterations in environmental and genetic rat models of ADHD: A pilot study. *Am J Med Genet B Neuropsychiatr Genet* 2008;147B(8):1554–1563. [PubMed: 18937310]
 92. Comings DE, et al. A “line item” approach to the identification of genes involved in polygenic behavioral disorders: the adrenergic alpha2A (ADRA2A) gene. *Am J Med Genet* 2003;118B(1):110–4. [PubMed: 12627476]
 93. Xu C, et al. Linkage study of the alpha2A adrenergic receptor in attention-deficit hyperactivity disorder families. *American Journal of Medical Genetics* 2001;105(2):159–62. [PubMed: 11304829]
 94. Roman T, et al. Is the alpha-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder? *Am J Med Genet* 2003;120B(1):116–20. [PubMed: 12815749]
 95. Park L, et al. Association and linkage of alpha-2A adrenergic receptor gene polymorphisms with childhood ADHD. *Mol Psychiatry* 2005;10(6):572–80. [PubMed: 15520832]
 96. Schmitz M, et al. Association Between Alpha-2a-adrenergic Receptor Gene and ADHD Inattentive Type. *Biol Psychiatry* 2006;60(10):1028–33. [PubMed: 16806103]

97. Stevenson J, et al. Characterizing the ADHD phenotype for genetic studies. *Dev Sci* 2005;8(2):115–21. [PubMed: 15720369]
98. Wang B, et al. Possible association of the alpha-2A adrenergic receptor gene (ADRA2A) with symptoms of attention-deficit/hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet* 2006;141B(2):130–4. [PubMed: 16389583]
99. Deupree JD, et al. Possible involvement of alpha-2A adrenergic receptors in attention deficit hyperactivity disorder: Radioligand binding and polymorphism studies. *Am J Med Genet B Neuropsychiatr Genet* 2006;141(8):877–84. [PubMed: 16917924]
100. Roman T, et al. Further evidence of the involvement of alpha-2A-adrenergic receptor gene (ADRA2A) in inattentive dimensional scores of attention-deficit/hyperactivity disorder. *Mol Psychiatry* 2006;11(1):8–10. [PubMed: 16172611]
101. Waldman ID, et al. The adrenergic receptor alpha-2A gene (ADRA2A) and neuropsychological executive functions as putative endophenotypes for childhood ADHD. *Cogn Affect Behav Neurosci* 2006;6(1):18–30. [PubMed: 16869226]
102. Safford SM, et al. A longitudinal look at parent-child diagnostic agreement in youth treated for anxiety disorders. *J Clin Child Adolesc Psychol* 2005;34(4):747–57. [PubMed: 16232071]
103. Comings D, et al. Additive effect of three noradrenergic genes (ADRA2A, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects. *Clinical Genetics* 1999;55(3):160–172. [PubMed: 10334470]
104. Barr CL, et al. Attention-deficit hyperactivity disorder and the adrenergic receptors alpha1C and alpha2C. *Molecular Psychiatry* 2001;6(3):334–7. [PubMed: 11326305]
105. De Luca V, et al. Adrenergic alpha 2C receptor genomic organization: Association study in adult ADHD. *Am J Med Genet* 2004;127B(1):65–7. [PubMed: 15108182]
106. Biederman J, Spencer T. Non-stimulant treatments for ADHD. *European Child and Adolescent Psychiatry* 2000;9(Suppl 1):151–9. [PubMed: 11140780]
107. Barr CL, et al. The norepinephrine transporter gene and attention-deficit hyperactivity disorder. *Am J Med Genet* 2002;114(3):255–9. [PubMed: 11920844]
108. McEvoy B, et al. No evidence of linkage or association between the norepinephrine transporter (NET) gene polymorphisms and ADHD in the Irish population. *Am J Med Genet* 2002;114(6):665–6. [PubMed: 12210284]
109. De Luca V, et al. Adrenergic alpha 2C receptor genomic organization: Association study in adult ADHD. *American Journal of Medical Genetics Part B (Neuropsychiatric Genetics)* 2004;127B:65–67.
110. Xu X, et al. DNA pooling analysis of 21 norepinephrine transporter gene SNPs with attention deficit hyperactivity disorder: No evidence for association. *Am J Med Genet B Neuropsychiatr Genet* 2005;134B(1):115–118. [PubMed: 15719398]
111. Bobb AJ, et al. Support for association between ADHD and two candidate genes: NET1 and DRD1. *Am J Med Genet B Neuropsychiatr Genet* 2005;134B(1):67–72. [PubMed: 15717291]
112. Kim CH, et al. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. *Proc Natl Acad Sci U S A* 2006;103(50):19164–9. [PubMed: 17146058]
113. Hawi Z, et al. Serotonergic system and attention deficit hyperactivity disorder (ADHD): a potential susceptibility locus at the 5-HT(1B) receptor gene in 273 nuclear families from a multi-centre sample. *Mol Psychiatry* 2002;7(7):718–25. [PubMed: 12192616]
114. Quist JF, et al. The serotonin 5-HT1B receptor gene and attention deficit hyperactivity disorder. *Mol Psychiatry* 2003;8(1):98–102. [PubMed: 12556913]
115. Smoller JW, et al. Association between the 5HT1B Receptor Gene (HTR1B) and the Inattentive Subtype of ADHD. *Biological Psychiatry* 2006;59(5):460–7. [PubMed: 16197923]
116. Heiser P, et al. Family-based association study of serotonergic candidate genes and attention-deficit/hyperactivity disorder in a German sample. *J Neural Transm* 2007;114(4):513–21. [PubMed: 17093889]
117. Quist JF, et al. Evidence for the serotonin HTR2A receptor gene as a susceptibility factor in attention deficit hyperactivity disorder (ADHD). *Molecular Psychiatry* 2000;5(5):537–41. [PubMed: 11032388]

118. Zoroglu SS, et al. Significance of serotonin transporter gene 5-HTTLPR and variable number of tandem repeat polymorphism in attention deficit hyperactivity disorder. *Neuropsychobiology* 2002;45(4):176–81. [PubMed: 12097805]
119. Li J, et al. No association of attention-deficit/hyperactivity disorder with genes of the serotonergic pathway in Han Chinese subjects. *Neurosci Lett*. 2006
120. Li J, et al. Contribution of 5-HT2A receptor gene -1438A>G polymorphism to outcome of attention-deficit/hyperactivity disorder in adolescents. *Am J Med Genet B Neuropsychiatr Genet*. 2006
121. Guimaraes AP, et al. Serotonin genes and attention deficit/hyperactivity disorder in a Brazilian sample: Preferential transmission of the HTR2A 452His allele to affected boys. *Am J Med Genet B Neuropsychiatr Genet* 2007;144(1):69–73. [PubMed: 16958038]
122. Levitan R, et al. Polymorphism of the serotonin-2A receptor gene (HTR2A) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder. *J Affect Disord* 2002;71(13):229–233. [PubMed: 12167522]
123. Li J, et al. Association between polymorphisms in serotonin 2C receptor gene and attention-deficit/hyperactivity disorder in Han Chinese subjects. *Neurosci Lett*. 2006
124. Li J, et al. Association of attention-deficit/hyperactivity disorder with serotonin 4 receptor gene polymorphisms in Han Chinese subjects. *Neurosci Lett*. 2006
125. Li J, et al. The serotonin 5-HT1D receptor gene and attention-deficit hyperactivity disorder in Chinese Han subjects. *Am J Med Genet B Neuropsychiatr Genet* 2006;141B(8):874–876. [PubMed: 17099886]
126. Anguelova M, Benkelfat C, Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: I. Affective disorders. *Mol Psychiatry* 2003;8(6):574–91. [PubMed: 12851635]
127. Anguelova M, Benkelfat C, Turecki G. A systematic review of association studies investigating genes coding for serotonin receptors and the serotonin transporter: II. Suicidal behavior. *Mol Psychiatry* 2003;8(7):646–53. [PubMed: 12874600]
128. Curran S, et al. The serotonin transporter gene as a QTL for ADHD. *Am J Med Genet B Neuropsychiatr Genet* 2005;134B(1):42–47. [PubMed: 15719397]
129. Kim SJ, et al. Family-based association study of the serotonin transporter gene polymorphisms in Korean ADHD trios. *Am J Med Genet B Neuropsychiatr Genet* 2005;139(1):14–8. [PubMed: 16082698]
130. Xu X, et al. Family-based association study of serotonin transporter gene polymorphisms in attention deficit hyperactivity disorder: No evidence for association in UK and Taiwanese samples. *Am J Med Genet B Neuropsychiatr Genet* 2005;139(1):11–3. [PubMed: 16082690]
131. Xu M, et al. Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. *Cell* 1994;79(6):945–55. see comments. [PubMed: 8001143]
132. Banerjee E, et al. A family-based study of Indian subjects from Kolkata reveals allelic association of the serotonin transporter intron-2 (STin2) polymorphism and attention-deficit-hyperactivity disorder (ADHD). *Am J Med Genet B Neuropsychiatr Genet* 2006;141(4):361–6. [PubMed: 16583436]
133. Wigg KG, et al. Gene for the serotonin transporter and ADHD: No association with two functional polymorphisms. *Am J Med Genet B Neuropsychiatr Genet* 2006;141B(6):566–570. [PubMed: 16856124]
134. Li J, et al. Association between polymorphisms in serotonin transporter gene and attention deficit hyperactivity disorder in Chinese Han subjects. *Am J Med Genet B Neuropsychiatr Genet* 2007;144(1):14–9. [PubMed: 16941663]
135. Manuck SB, et al. Aggression and anger-related traits associated with a polymorphism of the tryptophan hydroxylase gene. *Biol Psychiatry* 1999;45(5):603–14. [PubMed: 10088047]
136. Tang G, et al. Lack of association between the tryptophan hydroxylase gene A218C polymorphism and attention-deficit hyperactivity disorder in Chinese Han population. *American Journal of Medical Genetics* 2001;105(6):485–8. [PubMed: 11496362]

137. Li J, et al. [Association between tryptophan hydroxylase gene polymorphisms and attention deficit hyperactivity disorder with or without learning disorder]. *Zhonghua Yi Xue Za Zhi* 2003;83(24): 2114–8. [PubMed: 14720417]
138. Li J, et al. Association between tryptophan hydroxylase gene polymorphisms and attention deficit hyperactivity disorder in Chinese Han population. *Am J Med Genet B Neuropsychiatr Genet* 2006;141B:126–129. [PubMed: 16389593]
139. Sheehan K, et al. Tryptophan hydroxylase 2 (TPH2) gene variants associated with ADHD. *Mol Psychiatry* 2005;10(10):944–9. [PubMed: 15940290]
140. Walitza S, et al. Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder. *Mol Psychiatry* 2005;10(12):1126–32. [PubMed: 16116490]
141. Sheehan K, et al. No association between TPH2 gene polymorphisms and ADHD in a UK sample. *Neurosci Lett* 2007;412(2):105–7. [PubMed: 17123708]
142. Wilson MC. Coloboma mouse mutant as an animal model of hyperkinesia and attention deficit hyperactivity disorder. *Neuroscience and Biobehavioral Reviews* 2000;24(1):51–7. [PubMed: 10654661]
143. Barr CL, et al. Identification of DNA variants in the SNAP-25 gene and linkage study of these polymorphisms and attention-deficit hyperactivity disorder. *Molecular Psychiatry* 2000;5(4):405–9. [PubMed: 10889551]
144. Brophy K, et al. Synaptosomal-associated protein 25 (SNAP-25) and attention deficit hyperactivity disorder (ADHD): evidence of linkage and association in the Irish population. *Mol Psychiatry* 2002;7(8):913–7. [PubMed: 12232787]
145. Kustanovich V, et al. Biased paternal transmission of SNAP-25 risk alleles in attention-deficit hyperactivity disorder. *Mol Psychiatry* 2003;8(3):309–15. [PubMed: 12660803]
146. Mill J, et al. Association study of a SNAP-25 microsatellite and attention deficit hyperactivity disorder. *Am J Med Genet* 2002;114(3):269–71. [PubMed: 11920846]
147. Mill J, et al. Haplotype analysis of SNAP-25 suggests a role in the aetiology of ADHD. *Mol Psychiatry*. 2004
148. Feng Y, et al. The SNAP25 gene as a susceptibility gene contributing to attention-deficit hyperactivity disorder. *Mol Psychiatry* 2005;10(11):998–1005. 973. [PubMed: 16088329]
149. Kim JW, et al. Investigation of variation in SNAP-25 and ADHD and relationship to co-morbid major depressive disorder. *Am J Med Genet B Neuropsychiatr Genet*. 2007
150. Comings DE, et al. Multivariate analysis of associations of 42 genes in ADHD, ODD and conduct disorder. *Clinical Genetics* 2000;58(1):31–40. [PubMed: 10945659]
151. Kent L, et al. Nicotinic acetylcholine receptor alpha4 subunit gene polymorphism and attention deficit hyperactivity disorder. *Psychiatric Genetics* 2001;11(1):37–40. [PubMed: 11409698]
152. Todd RD, et al. Mutational analysis of the nicotinic acetylcholine receptor alpha 4 subunit gene in attention deficit/hyperactivity disorder: evidence for association of an intronic polymorphism with attention problems. *Mol Psychiatry* 2003;8(1):103–8. [PubMed: 12556914]
153. Lee J, et al. Association study of the nicotinic acetylcholine receptor alpha4 subunit gene, CHRNA4, in attention-deficit hyperactivity disorder. *Genes Brain Behav*. 2007
154. Turic D, et al. Follow-up of genetic linkage findings on chromosome 16p13: evidence of association of N-methyl-D aspartate glutamate receptor 2A gene polymorphism with ADHD. *Mol Psychiatry* 2004;9(2):169–73. [PubMed: 14966475]
155. Adams J, et al. Glutamate receptor, ionotropic, N-methyl D-aspartate 2A (GRIN2A) gene as a positional candidate for attention-deficit/hyperactivity disorder in the 16p13 region. *Mol Psychiatry* 2004;9(5):494–9. [PubMed: 14699423]
156. Egan MF, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. *Cell* 2003;112(2):257–69. [PubMed: 12553913]
157. Kent L, et al. Association of the paternally transmitted copy of common Valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene with susceptibility to ADHD. *Mol Psychiatry*. 2005

158. Xu X, et al. Family-based association study between brain-derived neurotrophic factor gene polymorphisms and attention deficit hyperactivity disorder in UK and Taiwanese samples. *Am J Med Genet B Neuropsychiatr Genet* 2007;144(1):83–6. [PubMed: 17044097]
159. Neale BM, et al. Genome-wide association scan of attention deficit hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet* 2008;147B(8):1337–1344. [PubMed: 18980221]
160. Lasky-Su J, et al. Genome-wide association scan of the time to onset of attention deficit hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet* 2008;147B(8):1355–1358. [PubMed: 18937294]
161. Lasky-Su J, et al. Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations. *Am J Med Genet B Neuropsychiatr Genet* 2008;147B(8):1345–1354. [PubMed: 18821565]
162. Lesch KP, et al. Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies. *J Neural Transm.* 2008
163. Doyle AE, et al. Attention-deficit/hyperactivity disorder endophenotypes. *Biol Psychiatry* 2005;57(11):1324–35. [PubMed: 15950005]
164. Doyle AE, et al. Neuropsychological functioning in youth with bipolar disorder. *Biological Psychiatry* 2005;58(7):540–548. [PubMed: 16199011]
165. Rommelse NN, et al. Neuropsychological endophenotype approach to genome-wide linkage analysis identifies susceptibility loci for ADHD on 2q21.1 and 13q12.11. *Am J Hum Genet* 2008;83(1):99–105. [PubMed: 18599010]